<DOC>
	<DOC>NCT01733368</DOC>
	<brief_summary>Optimization and evolution of the patient will be evaluated over 6 months after the implant.</brief_summary>
	<brief_title>QUARTO-II Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead</brief_title>
	<detailed_description>Patient will be enrolled into the study after Informed Consent signature and CRT-D+quadripolar (QuartetTM) LV lead.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient with implanted CRTD device and a QuartetTM quadripolar lead by St. Jude Medical in the left ventricle. Patient with an echocardiographic study performed during 1 month prior to the implant and in whom End Systolic Volume of the Left Ventricle (LVESV) has been measured Patients who have granted their informed consent. Patients above 18 years. Patients that have been previously resynchronized. Patients with aortic stenosis or aortic valve prosthesis Patients who are or may potentially be pregnant. Patients with a life expectancy &lt;12 months. Patients who cannot attend the monitoring visits established by the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CRT</keyword>
	<keyword>Optimization</keyword>
	<keyword>Responders</keyword>
</DOC>